ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements
Morepen Laboratories held its 41st Annual General Meeting on September 26, 2026, to conduct routine business, including dividend declaration and approval of director appointments.
Morepen Laboratories has been assigned an 'Adequate' ESG rating of 'CRISIL ESG 60' by Crisil ESG Ratings & Analytics Limited based on publicly disclosed information.
Morepen Laboratories successfully completed the first phase of its manufacturing capacity expansion. Installed reactor capacity for API and CDMO operations increased from 535 KL to 614 KL.
Morepen Laboratories dispatched a notice to shareholders without registered emails providing the Annual Report 2025-26 weblink. The company proposed a final dividend of ₹0.20 per share.
Morepen Laboratories has scheduled its 41st Annual General Meeting for September 26, 2026. The board has proposed a final dividend of ₹0.20 per equity share.
Morepen Laboratories secured a multi-year CDMO mandate worth approximately ₹825 Crore from a global pharmaceutical firm. This represents one of the largest single mandates in the company's history.
Morepen delivers explosive Q1'FY27 growth with 207% EBITDA jump, driven by the first commercial CDMO dispatches and operational leverage. The 'Morepen 2.0' strategy shifts focus from commodity APIs to high-margin innovation-led manufacturing.
Morepen Laboratories Ltd reported revenue from operations of ₹570.1 Cr (+34.1% YoY) and net profit of ₹56.3 Cr (+393.9% YoY) for Q1 FY27.
Morepen Labs reported Q4 FY26 revenue of ₹472 Cr, up 22% YoY, while shifting focus toward long-term CDMO contracts and high-margin medical devices.
Morepen Laboratories Ltd reported revenue from operations of ₹484.7 Cr (+4.0% YoY) and net profit of ₹15.7 Cr (-22.7% YoY) for Q4 FY26.